277 related articles for article (PubMed ID: 10362188)
1. A multicenter, randomized study of argatroban versus heparin as adjunct to tissue plasminogen activator (TPA) in acute myocardial infarction: myocardial infarction with novastan and TPA (MINT) study.
Jang IK; Brown DF; Giugliano RP; Anderson HV; Losordo D; Nicolau JC; Dutra OP; Bazzino O; Viamonte VM; Norbady R; Liprandi AS; Massey TJ; Dinsmore R; Schwarz RP
J Am Coll Cardiol; 1999 Jun; 33(7):1879-85. PubMed ID: 10362188
[TBL] [Abstract][Full Text] [Related]
2. A pilot trial of recombinant desulfatohirudin compared with heparin in conjunction with tissue-type plasminogen activator and aspirin for acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) 5 trial.
Cannon CP; McCabe CH; Henry TD; Schweiger MJ; Gibson RS; Mueller HS; Becker RC; Kleiman NS; Haugland JM; Anderson JL
J Am Coll Cardiol; 1994 Apr; 23(5):993-1003. PubMed ID: 8144799
[TBL] [Abstract][Full Text] [Related]
3. Efegatran sulfate as an adjunct to streptokinase versus heparin as an adjunct to tissue plasminogen activator in patients with acute myocardial infarction. ESCALAT Investigators.
Fung AY; Lorch G; Cambier PA; Hansen D; Titus BG; Martin JS; Lee JJ; Every NR; Hallstrom AP; Stock-Novack D; Scherer J; Weaver WD
Am Heart J; 1999 Oct; 138(4 Pt 1):696-704. PubMed ID: 10502216
[TBL] [Abstract][Full Text] [Related]
4. A Randomized, Blinded Study of Two Doses of Novastan(R) (Brand of Argatroban) Versus Heparin as Adjunctive Therapy to Recombinant Tissue Plasminogen Activator (Accelerated Administration) in Acute Myocardial Infarction: Rationale and Design of the Myocardial Infarction using Novastan(R) and T-PA (MINT) Study.
Serebruany VL; Jang IK; Giugliano RP; Massey TJ; Schwarz Jr
J Thromb Thrombolysis; 1998; 5(1):49-52. PubMed ID: 10608050
[TBL] [Abstract][Full Text] [Related]
5. Eptifibatide and low-dose tissue plasminogen activator in acute myocardial infarction: the integrilin and low-dose thrombolysis in acute myocardial infarction (INTRO AMI) trial.
Brener SJ; Zeymer U; Adgey AA; Vrobel TR; Ellis SG; Neuhaus KL; Juran N; Ivanc TB; Ohman EM; Strony J; Kitt M; Topol EJ
J Am Coll Cardiol; 2002 Feb; 39(3):377-86. PubMed ID: 11823073
[TBL] [Abstract][Full Text] [Related]
6. Catheter-directed thrombolysis with argatroban and tPA for massive iliac and femoropopliteal vein thrombosis.
Sharifi M; Bay C; Nowroozi S; Bentz S; Valeros G; Memari S
Cardiovasc Intervent Radiol; 2013 Dec; 36(6):1586-1590. PubMed ID: 23377239
[TBL] [Abstract][Full Text] [Related]
7. Combined accelerated tissue-plasminogen activator and platelet glycoprotein IIb/IIIa integrin receptor blockade with Integrilin in acute myocardial infarction. Results of a randomized, placebo-controlled, dose-ranging trial. IMPACT-AMI Investigators.
Ohman EM; Kleiman NS; Gacioch G; Worley SJ; Navetta FI; Talley JD; Anderson HV; Ellis SG; Cohen MD; Spriggs D; Miller M; Kereiakes D; Yakubov S; Kitt MM; Sigmon KN; Califf RM; Krucoff MW; Topol EJ
Circulation; 1997 Feb; 95(4):846-54. PubMed ID: 9054741
[TBL] [Abstract][Full Text] [Related]
8. TNK-tissue plasminogen activator compared with front-loaded alteplase in acute myocardial infarction: results of the TIMI 10B trial. Thrombolysis in Myocardial Infarction (TIMI) 10B Investigators.
Cannon CP; Gibson CM; McCabe CH; Adgey AA; Schweiger MJ; Sequeira RF; Grollier G; Giugliano RP; Frey M; Mueller HS; Steingart RM; Weaver WD; Van de Werf F; Braunwald E
Circulation; 1998 Dec 22-29; 98(25):2805-14. PubMed ID: 9860780
[TBL] [Abstract][Full Text] [Related]
9. Safety and Feasibility of Argatroban, Recombinant Tissue Plasminogen Activator, and Intra-Arterial Therapy in Stroke (ARTSS-IA Study).
Berekashvili K; Soomro J; Shen L; Misra V; Chen PR; Blackburn S; Dannenbaum M; Grotta JC; Barreto AD
J Stroke Cerebrovasc Dis; 2018 Dec; 27(12):3647-3651. PubMed ID: 30249518
[TBL] [Abstract][Full Text] [Related]
10. Low molecular weight heparin (dalteparin) compared to unfractionated heparin as an adjunct to rt-PA (alteplase) for improvement of coronary artery patency in acute myocardial infarction-the ASSENT Plus study.
Wallentin L; Bergstrand L; Dellborg M; Fellenius C; Granger CB; Lindahl B; Lins LE; Nilsson T; Pehrsson K; Siegbahn A; Swahn E
Eur Heart J; 2003 May; 24(10):897-908. PubMed ID: 12714021
[TBL] [Abstract][Full Text] [Related]
11. Combination reperfusion therapy with eptifibatide and reduced-dose tenecteplase for ST-elevation myocardial infarction: results of the integrilin and tenecteplase in acute myocardial infarction (INTEGRITI) Phase II Angiographic Trial.
Giugliano RP; Roe MT; Harrington RA; Gibson CM; Zeymer U; Van de Werf F; Baran KW; Hobbach HP; Woodlief LH; Hannan KL; Greenberg S; Miller J; Kitt MM; Strony J; McCabe CH; Braunwald E; Califf RM;
J Am Coll Cardiol; 2003 Apr; 41(8):1251-60. PubMed ID: 12706917
[TBL] [Abstract][Full Text] [Related]
12. Link between the angiographic substudy and mortality outcomes in a large randomized trial of myocardial reperfusion. Importance of early and complete infarct artery reperfusion. GUSTO-I Investigators.
Simes RJ; Topol EJ; Holmes DR; White HD; Rutsch WR; Vahanian A; Simoons ML; Morris D; Betriu A; Califf RM
Circulation; 1995 Apr; 91(7):1923-8. PubMed ID: 7895348
[TBL] [Abstract][Full Text] [Related]
13. Argatroban and alteplase in patients with acute myocardial infarction: the ARGAMI Study.
Vermeer F; Vahanian A; Fels PW; Besse P; Müller E; Van de Werf F; Fitzgerald D; Darius H; Puel J; Garrigou D; Simoons ML;
J Thromb Thrombolysis; 2000 Dec; 10(3):233-40. PubMed ID: 11122543
[TBL] [Abstract][Full Text] [Related]
14. Comparison of reperfusion regimens with or without tirofiban in ST-elevation acute myocardial infarction.
Martínez-Ríos MA; Rosas M; González H; Peña-Duque MA; Martínez-Sánchez C; Gaspar J; García H; Gaxiola E; Delgado L; Carrillo J; Leyva JL; Lupi E;
Am J Cardiol; 2004 Feb; 93(3):280-7. PubMed ID: 14759375
[TBL] [Abstract][Full Text] [Related]
15. High dose bolus heparin as initial therapy before primary angioplasty for acute myocardial infarction: results of the Heparin in Early Patency (HEAP) pilot study.
Verheugt FW; Liem A; Zijlstra F; Marsh RC; Veen G; Bronzwaer JG
J Am Coll Cardiol; 1998 Feb; 31(2):289-93. PubMed ID: 9462569
[TBL] [Abstract][Full Text] [Related]
16. Thrombolysis with recombinant unglycosylated single-chain urokinase-type plasminogen activator (saruplase) in acute myocardial infarction: influence of heparin on early patency rate (LIMITS study). Liquemin in Myocardial Infarction During Thrombolysis With Saruplase.
Tebbe U; Windeler J; Boesl I; Hoffmann H; Wojcik J; Ashmawy M; Rüdiger Schwarz E; von Loewis P; Rosemeyer P; Hopkins G
J Am Coll Cardiol; 1995 Aug; 26(2):365-73. PubMed ID: 7608436
[TBL] [Abstract][Full Text] [Related]
17. Comparison of front-loaded recombinant tissue-type plasminogen activator, anistreplase and combination thrombolytic therapy for acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) 4 trial.
Cannon CP; McCabe CH; Diver DJ; Herson S; Greene RM; Shah PK; Sequeira RF; Leya F; Kirshenbaum JM; Magorien RD
J Am Coll Cardiol; 1994 Dec; 24(7):1602-10. PubMed ID: 7963104
[TBL] [Abstract][Full Text] [Related]
18. Increased reperfusion by glycoprotein IIb/IIIa receptor antagonist administration in case of unsuccessful and failed thrombolysis in patients with acute myocardial infarction: a pilot study.
Di Pasquale P; Sarullo FM; Cannizzaro S; Vitrano MG; Giubilato A; Scalzo S; Giambanco F; Paterna S
Ital Heart J; 2001 Oct; 2(10):751-6. PubMed ID: 11721719
[TBL] [Abstract][Full Text] [Related]
19. A randomized factorial trial of reperfusion strategies and aspirin dosing in acute myocardial infarction. The DUCCS-II Investigators.
O'Connor CM; Meese RB; McNulty S; Lucas KD; Carney RJ; LeBoeuf RM; Maddox W; Bethea CF; Shadoff N; Trahey TF; Heinsimer JA; Burks JM; O'Donnell G; Krucoff MW; Califf RM
Am J Cardiol; 1996 Apr; 77(10):791-7. PubMed ID: 8623729
[TBL] [Abstract][Full Text] [Related]
20. Randomized comparison of enoxaparin, a low-molecular-weight heparin, with unfractionated heparin adjunctive to recombinant tissue plasminogen activator thrombolysis and aspirin: second trial of Heparin and Aspirin Reperfusion Therapy (HART II).
Ross AM; Molhoek P; Lundergan C; Knudtson M; Draoui Y; Regalado L; Le Louer V; Bigonzi F; Schwartz W; de Jong E; Coyne K;
Circulation; 2001 Aug; 104(6):648-52. PubMed ID: 11489769
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]